Watch the latest episode in the Pioneering Pathways interactive series to learn more about one mechanism of action that is being investigated to help address the unmet needs of patients living with post-traumatic stress disorder.
Bispecific antibodies are showing potential in the fight against HER2-expressing cancers. This innovative approach is designed to target two specific protein receptors, providing a new and effective way to treat aggressive forms of cancer that overexpress the HER2 protein. With their ability to simultaneously target two different antigens, bispecific antibodies offer a novel approach to treating solid tumors, including the possibility for new first-line treatments.
Given the limited recognition of idiopathic hypersomnia, there is not substantial data on the burden of symptoms on those living with the disorder. Recent real-world evidence from a self-reported survey published in Nature and Science of Sleep reveals more insights around idiopathic hypersomnia symptoms and patients’ satisfaction with treatment regimens.
As a long-time leader in neuroscience, Jazz has held a longstanding commitment to provide therapies and support for patients living with serious, debilitating neurologic disorders, to help them reclaim their lives. Even though essential tremor (ET) is considered the most common movement disorder, affecting millions of people worldwide,1 there are limited treatment options for patients.
